Journal of Aerosol Medicine and Pulmonary Drug Delivery
Scope & Guideline
Exploring new frontiers in aerosol therapy.
Introduction
Aims and Scopes
- Aerosol Drug Delivery Systems:
Research in this area includes the development and optimization of various aerosol drug delivery devices, such as metered-dose inhalers (MDIs), nebulizers, and dry powder inhalers (DPIs). Studies often focus on how device characteristics influence drug delivery efficiency and patient outcomes. - Pharmacokinetics and Pharmacodynamics of Inhaled Medications:
This includes investigations into the absorption, distribution, metabolism, and excretion of inhaled drugs. Understanding the pharmacokinetic profiles of medications delivered via aerosols is crucial for optimizing dosing regimens and therapeutic efficacy. - Innovative Formulation Development:
Research on novel formulations, including liposomal, nanoparticle, and polymer-based systems, aims to enhance the stability, solubility, and delivery of active pharmaceutical ingredients (APIs) through inhalation. - Clinical Outcomes and Patient-Centric Studies:
The journal emphasizes studies that evaluate the clinical effectiveness of aerosol therapies in real-world settings, focusing on patient adherence, usability of inhalation devices, and overall treatment outcomes. - In Vitro and In Vivo Models:
A significant portion of research employs advanced in vitro and in vivo models to simulate respiratory conditions and assess aerosol deposition, drug efficacy, and safety profiles.
Trending and Emerging
- Nanoparticle and Nanotechnology Applications:
Increasing interest in the use of nanoparticles for drug delivery, particularly for targeting lung diseases such as tuberculosis and cancer, highlights a shift toward more sophisticated and effective inhalation therapies. - Personalized Medicine Approaches:
Research into personalized inhalation therapies that consider individual patient characteristics and preferences is gaining traction, indicating a move towards more tailored therapeutic strategies. - Impact of E-Cigarettes and Vaping on Respiratory Health:
With the rise in vaping, studies examining the effects of e-cigarette aerosols on respiratory function and health outcomes are becoming more prevalent, reflecting public health concerns. - Advanced In Vitro Models for Drug Testing:
The development of sophisticated in vitro systems that mimic human respiratory conditions for drug testing is emerging as a critical area of research, enhancing the predictive value of preclinical studies. - Sustainability in Aerosol Delivery Devices:
There is a growing focus on developing environmentally sustainable inhaler technologies, particularly in response to regulatory pressures and public demand for greener pharmaceutical practices.
Declining or Waning
- Traditional Nebulization Techniques:
Research on conventional nebulizer systems appears to be declining as newer technologies, such as vibrating mesh nebulizers and soft mist inhalers, gain popularity for their efficiency and patient convenience. - Non-Inhalation Drug Delivery Methods:
There is a noticeable decrease in studies focusing on non-inhalation methods of drug delivery within the context of aerosol medicine, as the field shifts towards optimizing inhaled therapies specifically. - Basic Aerosol Science without Clinical Application:
While foundational aerosol science remains relevant, there seems to be a waning interest in purely theoretical studies that do not directly contribute to clinical applications or improvements in patient care. - Pharmacokinetics of Non-Respiratory Drugs:
Research focused on the pharmacokinetics of drugs not intended for respiratory diseases has diminished, as the journal's emphasis shifts towards inhaled therapies specifically tailored for respiratory conditions.
Similar Journals
Drug Delivery and Translational Research
Bridging Innovation and Application in Drug Delivery.Drug Delivery and Translational Research (ISSN: 2190-393X | E-ISSN: 2190-3948), published by Springer Heidelberg, stands at the forefront of the Pharmaceutical Sciences discipline, boasting a prestigious impact factor as evidenced by its Q1 category ranking in 2023. This esteemed journal is dedicated to the vital intersection of drug delivery systems and translational research, aiming to bridge the gap between laboratory findings and clinical applications. It features groundbreaking studies that enhance our understanding of drug pharmacokinetics, formulations, and patient-centered research, making it indispensable for researchers, professionals, and students striving to innovate and excel in the field. While the journal operates under a subscription model, its commitment to disseminating high-quality research is reflected in its Scopus rank, placing it in the top 6% of its category (Rank #11/183, 94th percentile). Since its inception in 2011, it has garnered significant attention, promoting advances in pharmacology, toxicology, and pharmaceutics, and continues to be a platform for vital discourse and discovery.
Frontiers in Pharmacology
Advancing pharmacological frontiers for a healthier tomorrow.Frontiers in Pharmacology, published by FRONTIERS MEDIA SA, stands as a leading open-access journal dedicated to advancing the field of pharmacology since its inception in 2010. With its ISSN 1663-9812, the journal is based in Switzerland and maintains a vital role in disseminating innovative research findings that span various disciplines within pharmacology, including pharmacokinetics, toxicology, and pharmacogenetics. In 2023, Frontiers in Pharmacology has achieved an impressive standing within the scientific community, being ranked in the Q1 category for both general and medical pharmacology, highlighting its critical contribution to the field with a Scopus ranking of #41 out of 272 in medical pharmacology and #76 out of 313 in pharmacology, toxicology, and pharmaceutics, placing it in the 75th and 85th percentiles, respectively. Researchers and practitioners benefit from its open-access model, which ensures widespread accessibility to groundbreaking research, fostering collaboration and innovation across the pharmaceutical sciences. With its commitment to excellence, Frontiers in Pharmacology serves as an essential resource for those looking to explore and contribute to the latest advancements in pharmacological research.
CURRENT DRUG TARGETS
Pioneering Discoveries in Drug DevelopmentCURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
Elevating Drug Delivery: Where Science Meets TechnologyThe Journal of Drug Delivery Science and Technology, published by Elsevier, stands at the forefront of pharmaceutical research, focusing on innovative drug delivery systems and technologies. With a robust impact factor reflected in its Q1 rating within the pharmaceutical sciences category, this journal is recognized for its high-quality contributions, ranking #30 out of 183 in the Scopus pharmacology and toxicology category (2023). Since its inception in 2004, the journal has been pivotal in disseminating groundbreaking research and advancements in drug formulation and delivery methodologies. Researchers and practitioners alike benefit from its comprehensive articles, which are accessible under open access options, ensuring widespread dissemination of knowledge. As it converges towards its 20th anniversary in 2024, the journal continues to enhance its impact on the scientific community, paving the way for future innovations in drug delivery.
Asian Journal of Pharmaceutical Research and Health Care
Catalyzing Change in Pharmaceutical Research and HealthcareAsian Journal of Pharmaceutical Research and Health Care, published by Wolters Kluwer Medknow Publications, serves as a vital platform for disseminating cutting-edge research in the fields of pharmacology, toxicology, and healthcare. With an ISSN of 2250-1444 and an E-ISSN of 2250-1460, this journal aims to provide valuable insights and advancements in pharmaceutical sciences, targeting researchers, practitioners, and students dedicated to improving health outcomes. Although its coverage in Scopus was discontinued in 2016, the journal maintains importance within the academic community by fostering discourse and sharing knowledge on emerging topics. Despite its challenges reflected in the low Scopus ranking within its category, the Asian Journal of Pharmaceutical Research and Health Care remains committed to enhancing access to critical research and publishing high-quality work that bridges the gap between theory and practice in health care. Researchers and professionals engaged in the pharmaceutical field are encouraged to contribute and leverage this journal as a means to advance their work and elevate healthcare standards in Asia and beyond.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Illuminating the path to ocular health advancements.JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.
Journal of Reports in Pharmaceutical Sciences
Fostering Excellence in Pharmaceutical Science Reporting.Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.
FARMACIA
Innovating Drug Development Through Rigorous Research.FARMACIA is a renowned academic journal published by the SOC STIINTE FARMACEUTICE ROMANIA, specializing in the field of pharmacology, toxicology, and pharmaceutics. With a rich history dating back to its initial publication years of 1945 to 1946, and ongoing contributions since 2008, the journal has established itself as a significant platform for disseminating cutting-edge research in the pharmaceutical sciences. Indexed in Scopus, it holds a commendable Q2 ranking in the Pharmacology, Toxicology and Pharmaceutics category, reflecting its importance in the field. The journal aims to foster knowledge sharing and innovation among researchers, professionals, and students alike, making it an essential resource for advancing pharmaceutical research. Although it does not currently offer Open Access, the content is accessible to a broad academic audience, ensuring valuable insights into current trends and discoveries in pharmacotherapy and drug development. For those seeking a deeper understanding of the evolving landscape of pharmaceutical sciences, FARMACIA provides a critical lens through which to explore and engage with the latest scientific advancements.
Pharmaceutical Sciences
Bridging research and practice to transform healthcare.Pharmaceutical Sciences, an esteemed journal published by Tabriz University of Medical Sciences, Faculty of Pharmacy, serves as a crucial platform for the dissemination of pioneering research in the fields of pharmaceutical science, pharmacology, and toxicology. With an impact factor reflective of its substantial contribution to the scientific community, this open access journal has been accessible since 2012, ensuring that researchers, professionals, and students worldwide can engage with its rich content. Located in Iran, it has continually evolved, covering research from 2009 to 2024, and boasts impressive rankings in multiple Scopus categories, including Q3 in Pharmaceutical Science and Q2 in Pharmacology, Toxicology and Pharmaceutics. By bridging gaps between scientific inquiry and practical applications, Pharmaceutical Sciences is dedicated to advancing pharmaceutical knowledge and promoting innovative practices that address significant health challenges.
DRUG DEVELOPMENT RESEARCH
Exploring the frontiers of drug discovery and development.DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.